Aptar Pharma Acquires Pulmonary Drug Delivery Specialist Pulmotree
Aptar Pharma (ATR) has announced the strategic acquisition of Pulmotree, a life science company based in Munich, Germany. The deal focuses on integrating Pulmotree's specialized expertise in pulmonary drug delivery systems into Aptar's existing portfolio. The acquisition is intended to accelerate the development, industrialization, and commercialization of advanced technologies designed for targeted lung drug delivery. This move strengthens Aptar's position within the respiratory segment of the life sciences market.
Tickers: $ATR
Topics: Life Sciences M&A Pulmonary Drug Delivery